Carregant...
Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
EGFR tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harboring activating mutations in the EGFR kinase(1,2), but resistance arises rapidly, most frequently due to the secondary T790M mutation within the ATP-site of the recep...
Guardat en:
| Publicat a: | Nature |
|---|---|
| Autors principals: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4929832/ https://ncbi.nlm.nih.gov/pubmed/27251290 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature17960 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|